查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085497

藥物濫用檢測市場：2026-2032年全球市場預測（按檢體類型、檢測技術、目標藥物和最終用戶分類）

Drug of Abuse Testing Market by Sample Type, Test Technology, Drug Panel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥物濫用檢測市場將成長至 101.2 億美元，複合年成長率為 8.06%。

主要市場統計數據
基準年 2025 58.8億美元
預計年份：2026年 63.4億美元
預測年份 2032 101.2億美元
複合年成長率 (%) 8.06%

引入藥物濫用檢測市場

隨著非法和非醫療用途藥物濫用日益複雜，包括高活性合成藥物、多種藥物混合使用以及區域性藥物濫用趨勢，藥物濫用檢測正成為風險管理、臨床實踐和公共安全的核心功能。根據聯合國毒品犯罪防制署（UNODC）發布的《2024年全球毒品報告》，2022年全球約有2.92億人使用毒品，較過去十年成長約20%。此外，約有6400萬人患有藥物濫用障礙。這種情況推動了醫院、診斷實驗室、法醫學機構、懲教機構、治療中心和受監管職場對可靠毒理學檢測的需求。

藥物檢測的變革性變化

隨著合成鴉片類藥物、新型苯二氮平類藥物、富含賽拉嗪的物質以及快速發展的新型大麻素產品對傳統檢測方案構成挑戰，藥物檢測格局正在經歷結構性轉變。在美國，疾病管制與預防中心（CDC）已將合成鴉片類藥物（主要是非法製造的Fentanyl）列為近期過量用藥死亡的主要原因之一。這迫使檢測實驗室和公共衛生計畫必須突破傳統的5項或10項藥物檢測的限制，採用更廣泛、更靈敏且更新更頻繁的檢測方法。

人工智慧（AI）的累積影響

人工智慧 (AI) 並非取代檢驗的毒理學科學，而是透過提高操作效率、分析結果解讀和資訊監控，為藥物濫用檢測創造累積價值。在高通量檢查室中，AI 驅動的工作流程工具可輔助檢體分類、儀器調度、品管審核和異常檢測，從而幫助消除商業性和臨床上對週轉時間要求極高的環境中的人工瓶頸。

藥物檢測的主要區域趨勢

在亞太地區，由於人口基數大規模、私人診斷網路不斷擴張以及交通、職場和邊境管制措施日益嚴格，藥物檢測需求不斷成長，篩檢數量也隨之增加。中國、印度、日本、韓國和澳洲都是主要的需求中心，其藥物檢測普及率受到都市化、執法機關現代化、道路安全計畫以及先進檢測基礎設施普及程度提高的影響。此外，該地區還出現了關於甲基安非他命和合成毒品走私和使用的擔憂，這凸顯了靈活、情境化毒理學檢測組合和確證性檢測的重要性日益增加。

對主要經濟和戰略集團的洞察

東協的需求主要受製造業、物流、港口和航空業擴張的驅動，這些產業的職業安全和合規性檢查變得日益重要。此外，該地區各國還面臨合成毒品走私模式的演變，包括國際禁毒機構報告的與甲基安非他命相關的壓力，因此，靈活的檢測方案、快速篩檢技術以及獲得用於確認性檢測的實驗室資源至關重要。

各國藥物檢測情況的關鍵訊息

美國是藥物濫用檢測市場最為多元化的國家，這得益於職場計畫、鴉片類藥物應對舉措、刑事司法檢測、治療監測、緊急醫療服務以及廣泛的認證檢測實驗室網路。加拿大市場則受到職場安全、大麻合法化、與鴉片類藥物相關的公共衛生需求以及對口腔液和確證檢測的需求的影響。墨西哥和巴西是拉丁美洲重要的成長市場，其需求與運輸、工業安全、執法、跨境毒品管制重點以及私人診斷能力的擴展密切相關。

為行業領導者提供的實用建議

產業領導者應制定靈活且視情況而定的檢測方案，其中包括Fentanyl、Fentanyl類似物、Buprenornhine、美沙酮、曲馬多、安非他命二氮平類藥物、合成大麻素、安非他明、可卡因代謝物、大麻標誌物、硝嗪、賽拉嗪（視當地情況而定）以及當地流行的新型精神藥物藥物。在毒品供應快速變化的市場中，固定檢測項目的效果較差。

調查方法

本執行摘要基於系統的二手資料和分析研究途徑，參考了檢驗的公共衛生、監管、科學和行業資訊來源。主要參考資料包括聯合國毒品和犯罪問題辦公室 (UNODC) 發布的《2024 年全球毒品報告》、美國疾病管制與預防中心 (CDC) 的過量用藥監測數據、各國政府衛生機構發布的國家毒品使用報告，以及經認可的職場、臨床和法醫學機構提供的檢測指南。

結論

藥物濫用檢測正從標準化的合規職能轉向動態的、數據驅動的毒理學生態系統。全球藥物濫用日益嚴重、合成鴉片類藥物的風險、大麻政策的分歧、職場安全要求以及公共衛生監測需求，都在推動臨床、法醫學、職業健康和公共安全等領域的需求成長。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：藥物濫用檢測市場：依樣本類型分類

  • 頭髮
  • 口腔液
  • 尿

第8章：藥物濫用檢測市場：依檢測技術分類

  • 層析法
    • GC-MS
    • LC-MS
      • LC-MS/MS
      • LC-QTOF
  • 免疫檢測

第9章：藥物濫用檢測市場：依藥物檢測小組分類

  • 可自訂面板
  • 擴充面板
  • 5題測試
  • 10題測試

第10章 藥物濫用檢測市場：依最終用戶分類

  • 臨床實驗室
  • 懲教設施
  • 法醫科學研究所
  • 醫院

第11章：藥物濫用檢測市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：藥物濫用檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 藥物濫用檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbott Laboratories
  • AccuBioTech Co., Ltd.
  • American Bio Medica Corporation
  • Bio-Rad Laboratories, Inc.
  • Clinical Reference Laboratory, LLC
  • Cordant Health Solutions Inc.
  • Danaher Corporation
  • Dragerwerk AG & Co. KGaA
  • Express Diagnostics International Inc.
  • F. Hoffmann-La Roche Ltd.
  • Laboratory Corporation of America Holdings
  • LGC Group Holdings Ltd.
  • LifeLoc Technologies, Inc.
  • MP Biomedicals, LLC
  • Omega Laboratories, Inc.
  • OraSure Technologies, Inc.
  • Precision Diagnostics Inc.
  • Premier Biotech, Inc.
  • Psychemedics Corporation
  • Quest Diagnostics Incorporated
  • Randox Laboratories Ltd.
  • Siemens Healthineers AG
  • SureScreen Diagnostics Ltd.
  • Thermo Fisher Scientific Inc.
  • Wondfo Biotech Co., Ltd.
Product Code: MRR-4348D129FA91

The Drug of Abuse Testing Market is projected to grow by USD 10.12 billion at a CAGR of 8.06% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.88 billion
Estimated Year [2026] USD 6.34 billion
Forecast Year [2032] USD 10.12 billion
CAGR (%) 8.06%

Drug of Abuse Testing Market Introduction

Drug of abuse testing is becoming a core risk-management, clinical, and public-safety function as illicit and nonmedical drug use evolves toward highly potent synthetic substances, polysubstance exposure, and region-specific drug trends. According to the UNODC World Drug Report 2024, an estimated 292 million people used drugs in 2022, up roughly 20% over the previous decade, while about 64 million people were living with drug use disorders. These conditions are increasing demand for reliable toxicology testing across hospitals, diagnostic laboratories, forensic agencies, correctional systems, treatment centers, and regulated workplaces.

The drug of abuse testing market is shaped by a dual requirement: fast screening and defensible confirmation. Immunoassay-based urine drug testing remains widely used for high-throughput screening, while liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry support confirmatory testing for complex analytes such as fentanyl analogs, benzodiazepines, synthetic cannabinoids, amphetamines, cocaine metabolites, and emerging novel psychoactive substances. Oral fluid, hair, and point-of-care drug testing are gaining relevance where observed collection, recent-use detection, and rapid decisions are operational priorities.

For industry leaders, growth is tied to clinical validity, chain-of-custody integrity, regulatory compliance, laboratory automation, and the ability to update test menus as drug supply patterns change. SEO-critical themes defining this market include drug of abuse testing, workplace drug testing, clinical toxicology, forensic toxicology, urine drug testing, oral fluid drug testing, fentanyl testing, confirmatory drug testing, and point-of-care toxicology testing.

Transformative Shifts in Drug Testing

The drug testing landscape is undergoing structural change as synthetic opioids, designer benzodiazepines, xylazine-adulterated substances, and rapidly changing cannabinoid products challenge legacy panel designs. In the United States, the CDC has identified synthetic opioids, primarily illicitly manufactured fentanyl, as the leading driver of overdose mortality in recent years. This has pushed laboratories and public-health programs to expand beyond traditional five-panel and ten-panel drug testing toward broader, more sensitive, and frequently updated assays.

A second shift is the movement from purely punitive testing to risk-based, clinically informed testing. Employers, health systems, treatment providers, and courts increasingly require results that can distinguish prescribed therapy from misuse, recent exposure from historical use, and screening presumptive positives from confirmed positives. This is accelerating adoption of confirmatory mass spectrometry, laboratory information management systems, and digitally traceable chain-of-custody workflows.

Testing matrices are also changing. Urine remains widely used because of cost, detection window, and established regulatory workflows, but oral fluid testing is expanding where collection observation and recent-use relevance matter. Hair testing continues to serve longer detection windows, especially in forensic and compliance contexts. The shift is not replacement; it is segmentation, with test type selected according to use case, analyte, legal defensibility, turnaround time, and budget.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value in drug of abuse testing by improving operational efficiency, analytical interpretation, and surveillance intelligence rather than replacing validated toxicology science. In high-volume laboratories, AI-enabled workflow tools can support specimen routing, instrument scheduling, quality-control review, and anomaly detection, helping reduce manual bottlenecks in environments where turnaround time is commercially and clinically important.

AI also strengthens interpretation when used under expert oversight. Machine learning can assist with chromatographic peak review, flag potential interferences, identify unusual metabolite patterns, and prioritize samples requiring toxicologist review. These capabilities are especially relevant for fentanyl analogs, synthetic cannabinoids, designer stimulants, nitazenes, and other novel psychoactive substances that may appear before standardized testing guidance is widely adopted.

The greatest strategic impact comes from connecting toxicology data with epidemiology, prescription monitoring, emergency department trends, and wastewater surveillance. When governed appropriately, AI can help detect emerging drug threats faster, guide test-menu updates, and improve operational planning for laboratories and point-of-care suppliers. However, adoption must remain anchored in validation, auditability, data privacy, bias control, and compliance with clinical laboratory and forensic quality standards.

Key Regional Insights for Drug Testing

Asia-Pacific is experiencing rising demand for drug of abuse testing as large population bases, expanding private diagnostics networks, and stricter transportation, workplace, and border-control programs increase screening volumes. China, India, Japan, South Korea, and Australia represent distinct demand centers, with adoption shaped by urbanization, law-enforcement modernization, roadside safety programs, and broader access to advanced laboratory infrastructure. The region also faces documented trafficking and use concerns around methamphetamine and synthetic drugs, making adaptable toxicology panels and confirmatory testing increasingly relevant.

North America remains one of the most mature regions for workplace drug testing, clinical toxicology, and forensic toxicology. The United States drives demand through employer programs, opioid-use disorder treatment monitoring, pain-management compliance, criminal justice testing, and public-health surveillance, while Canada's regulated cannabis environment and opioid crisis response sustain investment in laboratory and harm-reduction-linked testing. Latin America shows increasing adoption through workplace safety programs in mining, logistics, oil and gas, aviation, and law enforcement. Brazil and Mexico are central markets due to their industrial scale, expanding diagnostics networks, and cross-border drug-trafficking pressures.

Europe emphasizes harmonized quality, workplace safety, forensic reliability, and clinical toxicology capacity, with strong demand across Germany, France, Italy, Spain, and the United Kingdom. The Middle East, led by GCC countries, prioritizes strict drug-control policies, border security, aviation safety, and expatriate workforce screening. Africa remains an emerging market where demand is linked to public-sector capacity building, transport safety, occupational health, urban healthcare expansion, and the need for stronger surveillance systems to track changing drug-use patterns.

Key Economic and Strategic Group Insights

ASEAN demand is supported by expanding manufacturing, logistics, ports, and aviation sectors, where occupational safety and compliance testing are increasingly important. Countries in the region also face evolving synthetic drug trafficking patterns, including methamphetamine-related pressures reported by international drug-control agencies, making flexible test menus, rapid screening technologies, and confirmatory laboratory access strategically relevant.

The GCC is characterized by strict drug-control enforcement, high reliance on expatriate labor, and significant investment in healthcare and border-security infrastructure. These factors create demand for high-integrity testing systems, chain-of-custody controls, and confirmatory laboratory services. The European Union places strong emphasis on quality systems, privacy compliance, workplace health, and forensic defensibility, supporting demand for accredited laboratories, validated methods, and advanced mass spectrometry across clinical and forensic toxicology settings.

BRICS countries represent high-volume opportunity due to population scale, expanding diagnostics access, public-sector drug-control priorities, and industrial safety requirements across China, India, Brazil, Russia, and South Africa. G7 markets are more mature, with demand driven by clinical toxicology, opioid and polysubstance monitoring, road safety, cannabis policy variation, and regulated workplace programs. NATO countries add defense, security-clearance, transportation, and readiness-related testing requirements, making reliability, standardization, chain-of-custody integrity, and data security central procurement considerations.

Key Country Insights for Drug Testing

The United States is the most diversified drug of abuse testing market, supported by workplace programs, opioid-response initiatives, criminal justice testing, treatment monitoring, emergency care, and a broad network of certified laboratories. Canada's market is shaped by workplace safety, cannabis legalization, opioid-related public-health needs, and demand for oral fluid and confirmatory testing. Mexico and Brazil are important Latin American growth markets, with demand linked to transportation, industrial safety, law enforcement, cross-border drug-control priorities, and expanding private diagnostic capacity.

The United Kingdom combines workplace testing, clinical toxicology, road safety, and forensic demand, while Germany, France, Italy, and Spain benefit from established healthcare systems, accredited laboratories, occupational safety frameworks, and demand for legally defensible confirmatory testing. Russia's market is influenced by public-sector testing, forensic applications, workplace compliance, and drug-control enforcement priorities.

China and India represent scale-driven opportunities as diagnostics infrastructure expands and government focus on drug control remains strong. Japan emphasizes high-quality laboratory standards, workplace compliance, and precision in confirmatory testing, while Australia has a mature workplace and roadside testing environment, particularly in mining, transportation, and public safety. South Korea's demand is increasing with stronger enforcement attention, healthcare modernization, and growing awareness of emerging drug risks, including concerns around synthetic drugs and misuse of controlled substances.

Actionable Recommendations for Industry Leaders

Industry leaders should build adaptive test menus that include fentanyl, fentanyl analogs, buprenorphine, methadone, tramadol, benzodiazepines, synthetic cannabinoids, amphetamines, cocaine metabolites, cannabis markers, nitazenes, xylazine where regionally relevant, and locally prevalent novel psychoactive substances. Static panels are less effective in a market where drug supplies shift rapidly.

Organizations should pair rapid screening with confirmatory testing strategies that match the legal, clinical, or employment consequence of the result. Investment in LC-MS/MS capacity, validated oral fluid workflows, digital chain-of-custody systems, quality-management controls, and laboratory automation can improve defensibility and turnaround time.

Commercial teams should segment offerings by use case: workplace safety, treatment monitoring, forensic testing, emergency care, correctional programs, roadside testing, and public-health surveillance. Leaders that combine scientific rigor, regulatory awareness, AI-enabled operations, and region-specific market access will be best positioned for durable growth.

Research Methodology

This executive summary is developed using a structured secondary and analytical research approach based on verified public-health, regulatory, scientific, and industry sources. Key references include global drug-use evidence from the UNODC World Drug Report 2024, overdose surveillance from the U.S. CDC, national substance-use reporting from government health agencies, and testing guidance from recognized workplace, clinical, and forensic authorities.

The methodology applies data triangulation across epidemiology, regulatory frameworks, laboratory practice, technology adoption, and end-user demand. Market interpretation considers testing matrix, analyte class, application area, geography, and buyer type. Insights are reviewed for consistency with established toxicology practice, including presumptive screening, confirmatory testing, chain-of-custody requirements, laboratory accreditation, and quality-management standards.

No unsupported market-size, market-share, or forecasting claims are used. Emphasis is placed on verifiable trends, observed demand drivers, regulatory context, and technology adoption patterns that affect the drug of abuse testing market.

Conclusion

Drug of abuse testing is shifting from a standardized compliance function to a dynamic, data-driven toxicology ecosystem. Rising global drug use, synthetic opioid risks, cannabis policy divergence, workplace safety requirements, and public-health surveillance needs are expanding demand across clinical, forensic, occupational, and public-safety settings.

The strongest opportunities will come from validated testing portfolios that combine rapid screening, confirmatory mass spectrometry, flexible specimen matrices, digital chain-of-custody controls, and AI-supported laboratory workflows. Organizations that anticipate emerging analytes, align with regional regulations, and maintain scientific defensibility will lead the next phase of growth in the global drug of abuse testing market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drug of Abuse Testing Market, by Sample Type

  • 7.1. Hair
  • 7.2. Oral Fluid
  • 7.3. Urine

8. Drug of Abuse Testing Market, by Test Technology

  • 8.1. Chromatography
    • 8.1.1. Gc-Ms
    • 8.1.2. Lc-Ms
      • 8.1.2.1. Lc-Ms/Ms
      • 8.1.2.2. Lc-Qtof
  • 8.2. Immunoassay

9. Drug of Abuse Testing Market, by Drug Panel

  • 9.1. Customized Panel
  • 9.2. Expanded Panel
  • 9.3. Five Panel
  • 9.4. Ten Panel

10. Drug of Abuse Testing Market, by End User

  • 10.1. Clinical Laboratory
  • 10.2. Correctional Facility
  • 10.3. Forensic Laboratory
  • 10.4. Hospital

11. Drug of Abuse Testing Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Drug of Abuse Testing Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Drug of Abuse Testing Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. AccuBioTech Co., Ltd.
  • 15.3. American Bio Medica Corporation
  • 15.4. Bio-Rad Laboratories, Inc.
  • 15.5. Clinical Reference Laboratory, LLC
  • 15.6. Cordant Health Solutions Inc.
  • 15.7. Danaher Corporation
  • 15.8. Dragerwerk AG & Co. KGaA
  • 15.9. Express Diagnostics International Inc.
  • 15.10. F. Hoffmann-La Roche Ltd.
  • 15.11. Laboratory Corporation of America Holdings
  • 15.12. LGC Group Holdings Ltd.
  • 15.13. LifeLoc Technologies, Inc.
  • 15.14. MP Biomedicals, LLC
  • 15.15. Omega Laboratories, Inc.
  • 15.16. OraSure Technologies, Inc.
  • 15.17. Precision Diagnostics Inc.
  • 15.18. Premier Biotech, Inc.
  • 15.19. Psychemedics Corporation
  • 15.20. Quest Diagnostics Incorporated
  • 15.21. Randox Laboratories Ltd.
  • 15.22. Siemens Healthineers AG
  • 15.23. SureScreen Diagnostics Ltd.
  • 15.24. Thermo Fisher Scientific Inc.
  • 15.25. Wondfo Biotech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG OF ABUSE TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DRUG OF ABUSE TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DRUG OF ABUSE TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DRUG OF ABUSE TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG OF ABUSE TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL DRUG OF ABUSE TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HAIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HAIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HAIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORAL FLUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL FLUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORAL FLUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHROMATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHROMATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHROMATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GC-MS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GC-MS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GC-MS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LC-MS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LC-MS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LC-MS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LC-MS/MS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LC-MS/MS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LC-MS/MS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LC-QTOF MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LC-QTOF MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LC-QTOF MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CUSTOMIZED PANEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CUSTOMIZED PANEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CUSTOMIZED PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EXPANDED PANEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EXPANDED PANEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EXPANDED PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FIVE PANEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FIVE PANEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FIVE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TEN PANEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TEN PANEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TEN PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CLINICAL LABORATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CLINICAL LABORATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CLINICAL LABORATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CORRECTIONAL FACILITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CORRECTIONAL FACILITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CORRECTIONAL FACILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FORENSIC LABORATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FORENSIC LABORATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FORENSIC LABORATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GCC DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 113. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 114. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. G7 DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 134. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 135. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. NATO DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 140. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 141. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 142. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. CANADA DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 155. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 156. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 157. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 162. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 163. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 164. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 169. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 170. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 171. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED KINGDOM DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED KINGDOM DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED KINGDOM DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED KINGDOM DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED KINGDOM DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED KINGDOM DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED KINGDOM DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GERMANY DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. GERMANY DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GERMANY DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. GERMANY DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 183. GERMANY DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 184. GERMANY DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 185. GERMANY DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. FRANCE DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. FRANCE DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. FRANCE DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. FRANCE DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 190. FRANCE DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 191. FRANCE DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 192. FRANCE DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. RUSSIA DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. RUSSIA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. RUSSIA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. RUSSIA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 197. RUSSIA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 198. RUSSIA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 199. RUSSIA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. ITALY DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. ITALY DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ITALY DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. ITALY DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 204. ITALY DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 205. ITALY DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 206. ITALY DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. SPAIN DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. SPAIN DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. SPAIN DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. SPAIN DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 211. SPAIN DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 212. SPAIN DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 213. SPAIN DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. INDIA DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 225. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 226. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 227. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 232. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 233. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 234. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 239. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 240. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 241. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. SOUTH KOREA DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. SOUTH KOREA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. SOUTH KOREA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. SOUTH KOREA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 246. SOUTH KOREA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 247. SOUTH KOREA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 248. SOUTH KOREA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)